Baker Tilly Wealth Management LLC Buys 872 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Baker Tilly Wealth Management LLC lifted its stake in shares of Elanco Animal Health Incorporated (NYSE:ELANGet Rating) by 6.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 14,715 shares of the company’s stock after purchasing an additional 872 shares during the quarter. Baker Tilly Wealth Management LLC’s holdings in Elanco Animal Health were worth $418,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in ELAN. Franklin Resources Inc. increased its stake in Elanco Animal Health by 67.3% in the 3rd quarter. Franklin Resources Inc. now owns 11,854,595 shares of the company’s stock worth $378,043,000 after acquiring an additional 4,769,153 shares during the last quarter. Sculptor Capital LP bought a new position in Elanco Animal Health in the 3rd quarter worth about $138,752,000. Rockefeller Capital Management L.P. increased its stake in Elanco Animal Health by 58,874.1% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 2,658,554 shares of the company’s stock worth $84,779,000 after acquiring an additional 2,654,046 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Elanco Animal Health by 58.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 6,311,585 shares of the company’s stock worth $201,277,000 after acquiring an additional 2,334,220 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in Elanco Animal Health by 5.4% in the 3rd quarter. Wellington Management Group LLP now owns 22,947,541 shares of the company’s stock worth $731,798,000 after acquiring an additional 1,185,038 shares during the last quarter. Institutional investors own 97.90% of the company’s stock.

In related news, Director R David Hoover bought 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 1st. The stock was bought at an average cost of $28.66 per share, for a total transaction of $143,300.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 6.11% of the company’s stock.

Shares of Elanco Animal Health stock opened at $25.31 on Friday. The firm has a market capitalization of $11.98 billion, a PE ratio of -26.36, a price-to-earnings-growth ratio of 1.09 and a beta of 0.78. Elanco Animal Health Incorporated has a 12 month low of $24.15 and a 12 month high of $37.49. The business’s 50-day moving average price is $26.57 and its 200-day moving average price is $28.24. The company has a current ratio of 1.99, a quick ratio of 1.16 and a debt-to-equity ratio of 0.80.

Elanco Animal Health (NYSE:ELANGet Rating) last issued its earnings results on Thursday, February 24th. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.04. The company had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Elanco Animal Health had a positive return on equity of 6.59% and a negative net margin of 9.91%. Elanco Animal Health’s quarterly revenue was down 2.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.12 EPS. As a group, analysts predict that Elanco Animal Health Incorporated will post 1.2 earnings per share for the current fiscal year.

A number of brokerages have weighed in on ELAN. Zacks Investment Research upgraded Elanco Animal Health from a “sell” rating to a “hold” rating in a research note on Monday, February 28th. Barclays increased their price objective on Elanco Animal Health from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Monday, February 28th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $38.43.

About Elanco Animal Health (Get Rating)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Recommended Stories

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELANGet Rating).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.